Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide - Trial NCT06422325
Access comprehensive clinical trial information for NCT06422325 through Pure Global AI's free database. This phase not specified trial is sponsored by Oregon Health and Science University and is currently Not yet recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 35 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Oregon Health and Science University
Timeline & Enrollment
N/A
Jun 01, 2024
Dec 30, 2024
Primary Outcome
Incremental area under the curve of postprandial glucose following the first meal,Percent of time with sensed glucose between 70 - 180 mg/dl following first meal
Summary
The purpose of this study is to test how well a new investigational closed loop system
 manages your blood sugar with the ability to deliver insulin and pramlintide. Pramlintide is
 a drug that is used with mealtime insulin to control blood sugar in people who have diabetes.
 It works by slowing down the movement of food through the stomach which prevents blood sugar
 from rising too high after a meal. The closed loop system will receive glucose values from
 the Dexcom G6 CGM and automatically send commands to one Omnipod for insulin and one Omnipod
 for pramlintide delivery.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06422325
Device Trial